Sanofi un­veils $476M vac­cine plant in Sin­ga­pore, bring­ing its to­tal out­lay to $1.7B in the field for past year

5 years ago
Deals
Manufacturing

Taysha Gene Ther­a­pies gears up to ap­proach reg­u­la­tors with a new can­di­date for a de­bil­i­tat­ing neu­rode­gen­er­a­tive ...

5 years ago
Deals
Cell/Gene Tx

Re­gen­eron’s Covid mAb as a pro­phy­lac­tic in­jec­tion: Re­duced risk of symp­to­matic in­fec­tion by 81%

5 years ago
Pharma
Coronavirus

AACR21: Eli Lil­ly blazes new trail for RET in­hibitor, gin­ning up a re­sponse in 9 sol­id tu­mor types in ear­ly da­ta

5 years ago
R&D
Pharma

AACR21: iTeos busts out ear­ly hu­man da­ta for an­ti-TIG­IT an­ti­body. Is it enough to match up with Roche, Mer­ck?

5 years ago
R&D

AACR21: Zen­tal­is keeps the heat on As­traZeneca with ear­ly WEE1 da­ta show­ing a group of 'ex­cep­tion­al' re­spon­ders

5 years ago
R&D

AACR21 roundup: Ar­cus rolls out PhI da­ta on adeno­sine block­er for CRC; Co­di­ak's en­gi­neered ex­o­some for IL-12 shows ...

5 years ago
R&D

AACR21: Bris­tol My­ers looks to build Op­di­vo's case in ear­ly can­cer with full da­ta in pre-sur­gi­cal NSCLC

5 years ago
R&D

AACR21: As­traZeneca un­veils next-gen PARP in­hibitor, look­ing to fol­low up on suc­cess of first-gen suc­cess sto­ry ...

5 years ago
R&D

AACR21: Sanofi rolls out new da­ta for ear­ly-stage 'non-al­pha' IL-2. Ear­ly feed­back? In­ter­est­ing, but most­ly meh

5 years ago
R&D

The End­points 20 un­der 40, biotech's new nor­mal, Stéphane Bancel's one re­gret, and more

5 years ago
Weekly

Sanofi CEO Paul Hud­son dives deep­er in­to mR­NA, buy­ing out an un­der-the-radar Fred Hutch spin­out

5 years ago
Deals

Biden’s bud­get wish list: Re­store the CDC, build a new NIH re­search cen­ter, pump in bil­lions to end the opi­oid and ...

5 years ago
Coronavirus

Lay­ing claim to an­oth­er AI 'first,' Ex­sci­en­tia tees up an I/O drug for the clin­ic

5 years ago
R&D
AI

John Robin­son re­cruits a small band of Ar­ray vets to kick­start dis­cov­ery at Co­gent; Syn­tim­mune co-founder takes ...

5 years ago
Peer Review

AACR: Ger­many's small NK cell play­er Af­fimed makes a big splash with ear­ly lym­phoma da­ta

5 years ago
R&D

The num­bers are in, and new Ver­tex CEO Resh­ma Ke­wal­ra­mani took home half of what pre­de­ces­sor Jeff Lei­den did in his ...

5 years ago
People

Can he pick them? A high-pro­file Wall Street an­a­lyst jumps in­to biotech as CFO of an on­col­o­gy up­start

5 years ago
People
Bioregnum

Seat­tle-based Remiges Ven­tures to launch in­cu­ba­tor af­ter heavy in­vest­ment from Japan; Schrödinger signs lease on new ...

5 years ago
News Briefing

EMA in­ves­ti­gat­ing 4 'se­ri­ous cas­es' of blood clots fol­low­ing J&J vac­ci­na­tions

5 years ago
FDA+
Coronavirus

Covid-19 roundup: Lil­ly/In­cyte's Olu­mi­ant plus remde­sivir com­bo whiffs PhI­II; France rec­om­mends mix­ing vac­cines among ...

5 years ago
Coronavirus

CBO: Con­gres­sion­al ac­tion on drug prices will make R&D spend­ing less at­trac­tive

5 years ago
Pharma
FDA+

MPM-backed Were­wolf, Mer­ck-part­nered Arti­va make quick IPO flip while Lu­ca Santarel­li's biotech rais­es $127.5M

5 years ago
Financing

Scoop: Fer­ring, Black­stone’s $570M gene ther­a­py ven­ture has im­plod­ed af­ter CMC is­sues stymied a once high-pro­file ...

5 years ago
FDA+
Manufacturing
First page Previous page 719720721722723724725 Next page Last page
A service from the Financial Times